Merck & Company Inc (MRK)
NYSE Market Closed
Merck & Co., Inc. is a global pharmaceutical company that develops and sells prescription medicines, vaccines, biologic therapies, and animal health products. The company, known as MSD outside the United States and Canada, operates across major therapeutic areas including oncology, infectious disease, cardiometabolic disorders, immunology, and vaccines. Its scale, research base, and commercial reach make it one of the most important drugmakers in the global healthcare sector.
Merck’s largest growth driver is its oncology franchise, led by Keytruda, an immunotherapy used across multiple cancer types. Keytruda works by helping the immune system recognize and attack cancer cells, and it has become central to modern cancer treatment in many indications. Beyond oncology, Merck has a significant vaccines business, including products used in pediatric immunization and Gardasil, which helps protect against diseases caused by human papillomavirus.
The company also participates in infectious disease treatment and prevention, as well as selected areas of cardiometabolic care. In addition to human health, Merck operates an animal health division that supplies medicines, vaccines, and related products for livestock and companion animals, adding diversification beyond its core pharmaceutical portfolio.
Merck’s financial performance depends on patent protection, clinical trial success, regulatory approvals, pricing dynamics, and global healthcare demand. The United States is a major market for its human health products, but the company also sells extensively internationally. For investors, Merck represents exposure to a large research-driven pharmaceutical business with a leading cancer platform, a durable vaccines portfolio, and a meaningful presence in animal health.
Last updated
- Market Cap
- $307,246,157,226
- P/E
- 34.39
- P/FCF
- 21.77
- P/S
- 4.67
- Enterprise Value
- $351,036,157,226
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Address
- 126 EAST LINCOLN AVENUE, RAHWAY, NJ, 07065
Trade Options When Others Are Fearful
Gilead (GILD) Will Bring New HIV Data And A Merck Regimen To AIDS 2026
Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Merck (NYSE:MRK)
Merck (MRK) Declines More Than Market: Some Information for Investors
Tempus AI Scoops Up Personalis For $1.5 Billion; But Shares Dive
What Comes After Merck’s Keytruda? The Race for the Next Standard Cancer Treatment.
Merck (MRK) Wins FDA Approval For First Oral PCSK9 Cholesterol Drug
IHE vs. BBH: Which Healthcare ETF Is the Better Buy Right Now?
Weekly Buzz: NVS, MRK Win FDA Nod; LLY Snaps Up ATAI; MANE Shines On Hair Loss Data
Gilead Leads The Battle Vs. HIV. But Rivals Are On The Move.
Merck Reportedly Goes To Bat In Takeover Battle. Genomics Stock Flies.
Stocks Settle Lower as Chipmakers and AI Stocks Slump
Merck (MRK) Stock Sees Modest Fair Value Lift As Analysts Raise Targets
Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
Which Pharmaceuticals ETF Is Better, the iShares IHE or State Street XPH?
Merck Opens BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe
Prediction: This Dividend King Could End The Year With a New All-Time High Stock Price
Update: US Equity Futures Higher Pre-Bell Amid Inflation Data, Middle East Tensions
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday Amid Economic Reports
Eupraxia Pharmaceuticals Appoints New Technical Operations Heads; Co-Founder Malone Steps Down
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- $307,246,157,226
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- $351,036,157,226
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 34.39
- P/B
P/B ratio compares a company's share price to its book value per share.
- 6.7
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 4.67
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 18.26
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 5.34
- EPS
- 3.62
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 2.68%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 21.77
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 17.17
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- $14,115,000,000
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 19.48%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 6.94%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 1.07
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 1.3
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 1.06
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 0.2
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- $11,474,295
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 124.4
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 16.29B | 16.4B | 17.28B | 15.81B | 15.53B |
| Cost of revenue | 4.2B | 5.55B | 3.86B | 3.56B | 3.42B |
| Gross profit | 12.09B | 10.85B | 13.42B | 12.25B | 12.11B |
| Operating income | -3.4B | 3.85B | 6.51B | 4.99B | 5.87B |
| EBITDA | -1.69B | 6.53B | 7.71B | 6.67B | 7.04B |
| Net income | -4.24B | 2.96B | 5.79B | 4.43B | 5.08B |
| Income taxes | 709M | 458M | 958M | 571M | 818M |
| Other operating expenses | 195M | 213M | 47M | 560M | 69M |
| Total operating expenses | 15.49B | 7B | 6.91B | 7.26B | 6.24B |
| Basic EPS | -1.72 | 1.21 | 2.32 | 1.76 | 2.01 |
| Diluted EPS | -1.72 | 1.2 | 2.32 | 1.76 | 2.01 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 128.69B | 136.87B | 129.55B | 117.52B | 115.12B |
| Total liabilities | 82.75B | 84.2B | 77.64B | 68.46B | 66.72B |
| Total equity | 45.93B | 52.66B | 51.91B | 49.06B | 48.4B |
| Cash & equivalents | 5.33B | 14.57B | 18.17B | 8.01B | 8.63B |
| Current assets | 35.02B | 43.52B | 47.56B | 37.07B | 35.5B |
| Current liabilities | 26.95B | 28.33B | 28.63B | 26.04B | 25.17B |
| Accounts payable | 3.86B | 4.4B | 4.15B | 3.89B | 3.78B |
| Receivables | 12.21B | 11.78B | 12.12B | 11.85B | 10.79B |
| Inventories | 6.48B | 6.66B | 6.44B | 6.6B | 6.2B |
| Goodwill | 21.58B | 21.58B | 21.59B | 21.59B | 21.68B |
| Long-term debt | 46.67B | 46.75B | 39.97B | 33.97B | 33.48B |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | 3.92B | 2.86B | 7.82B | 3.29B | 2.5B |
| Investing cash flow | -10.21B | -11.2B | -283M | -770M | -1.49B |
| Financing cash flow | -2.98B | 4.75B | 2.64B | -3.56B | -5.76B |
| Change in cash | -9.29B | -3.57B | 10.19B | -659M | -4.59B |
| Net income | -4.24B | 2.96B | 5.79B | 4.43B | 5.09B |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| form 4 | Form 4 — Coe Mary Ellen | View Filing | |
| form 4 | Form 4 — Coe Mary Ellen | View Filing | |
| form 4 | Form 4 — Karsanbhai Surendralal Lanca | View Filing | |
| form 4 | Form 4 — Karsanbhai Surendralal Lanca | View Filing | |
| form 4 | Form 4 — Seidman Christine E | View Filing | |
| form 4 | Form 4 — Seidman Christine E | View Filing | |
| edgar index | 11-K — Merck & Co., Inc. | View Filing | |
| edgar index | 11-K — Merck & Co., Inc. | View Filing | |
| edgar index | 11-K — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | SD — Merck & Co., Inc. | View Filing | |
| form 4 | Form 4 — BAKER DOUGLAS M JR | View Filing | |
| form 4 | Form 4 — BAKER DOUGLAS M JR | View Filing | |
| form 4 | Form 4 — Craig Pamela J. | View Filing | |
| form 4 | Form 4 — Craig Pamela J. | View Filing | |
| form 4 | Form 4 — GLOCER THOMAS H | View Filing | |
| form 4 | Form 4 — GLOCER THOMAS H | View Filing | |
| form 4 | Form 4 — LAVIZZO-MOUREY RISA J | View Filing | |
| form 4 | Form 4 — LAVIZZO-MOUREY RISA J | View Filing | |
| form 4 | Form 4 — Mayo Stephen | View Filing | |
| form 4 | Form 4 — Mayo Stephen | View Filing | |
| form 4 | Form 4 — Rothman Paul | View Filing | |
| form 4 | Form 4 — Rothman Paul | View Filing | |
| form 4 | Form 4 — RUSSO PATRICIA F | View Filing | |
| form 4 | Form 4 — RUSSO PATRICIA F | View Filing | |
| form 4 | Form 4 — Seidman Christine E | View Filing | |
| form 4 | Form 4 — Seidman Christine E | View Filing | |
| form 4 | Form 4 — THULIN INGE G | View Filing | |
| form 4 | Form 4 — THULIN INGE G | View Filing | |
| form 4 | Form 4 — Coe Mary Ellen | View Filing | |
| form 4 | Form 4 — Coe Mary Ellen | View Filing | |
| form 4 | Form 4 — Karsanbhai Surendralal Lanca | View Filing | |
| form 4 | Form 4 — Karsanbhai Surendralal Lanca | View Filing | |
| form 4 | Form 4 — Warden Kathy J | View Filing | |
| form 4 | Form 4 — Warden Kathy J | View Filing | |
| edgar index | 8-K — Merck & Co., Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — Merck & Co., Inc. | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 424B5 — Merck & Co., Inc. | View Filing | |
| edgar index | FWP — Merck & Co., Inc. | View Filing | |
| edgar index | 424B5 — Merck & Co., Inc. | View Filing | |
| edgar index | 13F-HR — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 3/A — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | 4 — Merck & Co., Inc. | View Filing | |
| edgar index | SC TO-T/A — Merck & Co., Inc. | View Filing | |
| form 3 | Form 3 — Maraldo David R. | View Filing | |
| form 3 | Form 3 — Maraldo David R. | View Filing |
- Trusted by 1M+ investors
- Global coverage
- Real-time market data
- Independent & unbiased
Join thousands making smarter investment decisions.
Get started for free